Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947941 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 325
- Enrollment target
NCT06947941 is a Phase 3 study that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 325 participants.
The verdict
NCT06947941, a Phase 3 study, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 325 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Interventions
- DRUG KarXT
- DRUG KarX-EC
- DRUG KarXT + KarX-EC Arm Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2026-03-25 |
| Est. Completion | 2028-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06947941
The ClinicalTrials.gov registry entry for NCT06947941 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which KarXT is the first listed.
NCT06947941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06947941 about?
NCT06947941 is a clinical study titled "A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)". The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
What is the current status of trial NCT06947941?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 325 participants. The study started on 2026-03-25. Estimated completion is 2028-03-20.
What interventions are being tested in trial NCT06947941?
The interventions under investigation include: KarXT (DRUG), KarX-EC (DRUG), KarXT + KarX-EC Arm Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT06947941?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.